An Overview of Pharmacovigilance and Adverse Drug Reaction Monitoring of Drugs and Vaccines during the COVID-19 Pandemic

Abstract

Once a drug is approved in phase III of clinical trials, pharmacovigilance (PV) becomes very important for the surveillance of drug, vaccine or medical devices. PV constitutes part of the phase IV approval, which involves a study for collecting, detecting, and monitoring adverse events in any population that the drug is used. The adverse events that are reported must be assessed to ascertain the causal effects and prevent or avoid unanticipated side effects on the population. With the advent of the coronavirus disease 2019 (COVID-19) pandemic, vaccination has been the motor for the management of the pandemic, and through intensive health sensitization, more people are vaccinated in a short period leading to greater challenges to the PV taskforce and the PV operating centrers. Global partnerships including the international society of pharmacovigilance (ISOP), the French national agency for medicines and health products safety (ANSM), and a multitude of others are working in synergy towards putting in place a continuous collaboration work package with many sensitization, education, capacity building, and research initiatives. This is within the framework of identifying the safety and efficacy of vaccines in order to provide solutions to emerging challenging ethical questions.
 Through PV, signal detection is in progress for the identification of adverse events. The unanticipated emergence and negative impact of COVID-19, caused by the severe acute respiratory syndrome virus 2 (SARS-CoV-2) has significantly compelled global pharmacists and drug actors to collectively play an important role in the management of COVID-19. This has to be done within the framework of therapeutic strategies and guaranteed safety, efficacy and quality of new and old xenobiotics. In the current treatment COVID-19 has created health-related challenges and a shift in paradigm in drug discovery and development of new chemical entities (NCE), for vaccine or drug repurposing for different levels of treatment interventions. The accelerated interest in dynamic research and innovation have led to different approaches of treatment and this has come with potential side effects, which has led to the call for post marketing surveillance and monitory. PV is therefore a key component for phase IV study for the drugs and vaccines approved for global use. This paper gives an insight into the global PV monitoring and surveillance of new chemical entities (drugs and vaccines) and new technologies targeting the management of COVID-19.

Redefining Healthcare With Artificial Intelligence (AI): The Contributions of ChatGPT, Gemini, and Co-pilot

“…External certification and peer evaluations by medical professionals further solidify AI systems' reliability, providing an added layer of trust and ensuring AI applications contribute positively to healthcare outcomes [22][23][24][25][26][27][28][29][30][31].…”

An Overview of Pharmacovigilance Practice and Management in Sub-Saharan African Countries

“…A low-cost VigiFlow system, established by UMC, can be used to manage drug safety information at the national level and to share the data globally through VigiBase. SSA countries that are members of the WHO Programme for International Drug Monitoring (WHO-PIDM), can apply VigiLyze to conduct signal detection analyses on national, regional and global safety data in VigiBase, promoting international collaboration [8,23]. High income countries (HIC) use a combination of manual and complex statistical tools with programmed criteria applied to very large complex pharmacovigilance databases that is ahead of human capacity for manual reviews [3,24].…”

“…The US Food and Drug Administration (USFDA), and UK Medicines and Healthcare products Regulatory Agency (UK-MHPRA) for example use Quantitative Signal Detection Algorithms (QSDA) in their pharmacovigilance systems [5,25]. However, the current version of VigiLyze provides the same kind of statistical analysis as Quantitative Signal Detection Algorithms, and is accessible to all member countries of the WHO-PIDM [23,26]. It has been reported that methods to enhance signal detection and interpretation, and the prediction of ADRs at both the individual and community levels is evolving, and explore more areas where disparity between HIC and LMIC may continue to widen.…”